Skip to content
Menu

Enovis Corporation ENOV

Full chart Compare
Set alert

Price alert · ENOV

All alert types
25.93 USD -0.30 (-1.16%)

As ofNov 20, 2026, 12:08 PM EST

25.64 Day range 26.62
16.70 52-week range 31.67
YTD
-2.68%
1 year
-3.37%

5D -1.87 (-6.65%)

26272829FriMonTueWedThu26.23
Market cap
1.50B
Revenue (ttm)
2.31B
Profit margin
-22.87%
EPS (ttm)
-9.23
Shares out
57.69M
Forward P/E
7.58
YTD return
-2.68%
1-year return
-3.37%
50-day average
21.02
200-day average
23.31
Volume
196.52K
Avg volume
1.70M
Open
26.16
Previous close
26.23
Day's range
25.64 – 26.62
52-week range
16.70 – 31.67
Beta
1.42
Analysts
Strong Buy
Price target
37.83 (+45.9%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
2.90B
PEG ratio
3.45
Price / sales
0.66
Price / book
1.01
Revenue growth
1.80%
Free cash flow
151.48M
Total cash
13.04M
Total debt
1.34B
Return on equity
-29.95%
Short % of float
21.81%

Fundamental scorecard

6 of 25 checks passed on ENOV’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Oct 2, 2026.

Financials — quick view

All financials
ENOV Revenue — quarterly 558.73M
ENOV Net income — quarterly 3.14M
ENOV EPS — quarterly 0.06

Earnings

ENOV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Jan 2, 20271.01———
Nov 5, 2026Oct 2, 20260.7670.88+0.11+14.73%
Aug 6, 2026Jul 3, 20260.8470.90+0.05+6.26%
May 7, 2026Apr 3, 20260.820.89+0.07+8.54%
Feb 26, 2026Dec 31, 20250.810.95+0.14+17.28%
Nov 6, 2025Oct 3, 20250.670.75+0.08+11.94%

Upgrades / downgrades

ENOV analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Canaccord GenuitymainBuyBuy
Nov 6, 2026Evercore ISI GroupmainOutperformOutperform
Nov 6, 2026Wells FargomainOverweightOverweight
Nov 5, 2026NeedhammainBuyBuy
Nov 5, 2026BTIGmainBuyBuy
Oct 12, 2026NeedhammainBuyBuy

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
enovis.com

News

Your note

Sign in to keep a note on ENOV — it syncs with the Stock Master app.

Insider holders

ENOV insider holders
InsiderRelationLatest transactionDateShares held
BERRY PHILLIP BENJAMIN BENChief Financial OfficerStock Award(Grant)Mar 8, 2026158,596
ENGERT OLIVEROfficerPurchaseSep 3, 202663,898
LANG PATRICIA AOfficerStock Award(Grant)Mar 8, 202675,703
MCDONALD DAMIENChief Executive OfficerPurchaseSep 3, 2026247,077
PRYOR DANIEL ALEXISFormerSaleDec 8, 20250
ROSS TERRY DOfficerStock Award(Grant)Mar 8, 202668,477

Institution ownership

ENOV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.88%10,313,312270.62MSep 29, 2026
American Century Companies Inc11.94%6,889,905180.79MSep 29, 2026
Rubric Capital Management LP9.19%5,300,000139.07MSep 29, 2026
Vanguard Portfolio Management LLC6.45%3,718,44997.57MSep 29, 2026
State Street Corporation4.34%2,501,63665.64MSep 29, 2026
Vanguard Capital Management LLC4.25%2,449,75764.28MSep 29, 2026

Fund ownership

ENOV fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%3,431,56990.04MSep 29, 2026
American Century Capital Portfolios, Inc.-Small Cap Value Fund3.88%2,240,00058.78MSep 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.79%2,189,18257.44MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Value Fund3.52%2,032,40653.33MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%1,719,53045.12MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.59%1,493,64339.19MSep 29, 2026